NAMS · NewAmsterdam Pharma Co N.V. · Executive Compensation
Market Cap
$2.58B
Shares
119.54M
Volume · Oct 9
1.27M
Avg daily vol (3M)
1.36M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Davidson | Chief Executive Officer | $5,832,558 |
| Ian Somaiya | Chief Financial Officer | $3,553,069 |
| John Kastelein | M.D., Ph.D. FESC Chief Scientific Officer | $2,978,571 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robert W. Gunning | principal accounting officer | Appointed | 2026-08-14 |
| Douglas Kling | Chief Operating Officer | Resigned | 2026-07-22 |
| Louise Kooij | Chief Accounting Officer | Terminated | 2026-04-24 |
| Adele Gulfo | member of the Board | Appointed | 2025-04-17 |
| Mark C. McKenna | temporary non-executive director | Appointed | 2024-07-18 |
| Wouter Joustra | temporary non-executive director | Appointed | 2024-07-18 |
| Sander Slootweg | member of the Company's board of directors | Resigned | 2024-07-18 |
| Juliette Audet | Board of Directors | Resigned | 2024-04-01 |
| Juliette Audet | Chief Business Officer | Appointed | 2024-04-01 |